Smart Choices for Lowering Cholesterol: A Look at New Medications

Introduction of PCSK-9 Inhibitors and Inclisiran

In the Moscow Region, doctors are now using new drugs to help people with high cholesterol. These drugs are:

• PCSK-9 inhibitors (alirocumab and evolocumab)
• Inclisiran

They work in different ways to lower cholesterol levels.

Research Findings

Researchers looked at how many people might need these drugs:

• First Year: About 12,228 people might use a mix of high-dose statins and one of these new drugs.
• Third Year: This number could go up to 12,973 people.

Cost Comparison

The cost of these new drugs is a big question:

• First Year:
• Inclisiran is cheaper than evolocumab and alirocumab.
• It's about 23.31% cheaper than evolocumab.

• It's about 27.66% cheaper than alirocumab.

• Total Cost:
• The total cost of treating all these patients is expected to go up a little bit each year.
• This is mostly because more people are being diagnosed with high cholesterol, not because the drugs are more expensive.

Reliability Check

The researchers also checked if their results were reliable:

• Even if some of their guesses were a bit off, the overall results still held up.

Conclusion

Using these new drugs as part of a combination therapy seems to be a smart choice:

• It can help people with high cholesterol and a high risk of heart problems.
• It won't break the bank.